Genmab A/S
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $963.0M | $1.13B | $631.0M |
| Depreciation & Amortization | — | — | — |
| Depreciation | — | — | — |
| Amortization | — | — | — |
| Stock-Based Compensation | $128.0M | $105.0M | $85.0M |
| Net Cash from Operating Activities | $1.19B | $1.13B | $1.07B |
| Investing Activities | |||
| Capital Expenditures | $37.0M | $27.0M | $53.0M |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | $-5.64B | $-1.45B | $-185.0M |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | $430.0M | $560.0M | $81.0M |
| Net Cash from Financing Activities | $4.79B | $-566.0M | $-89.0M |
| Net Change in Cash | — | — | — |
| Free Cash Flow | $1.15B | $1.10B | $1.02B |